These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 35812369)

  • 1. IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
    Yi X; Zheng X; Xu H; Li J; Zhang T; Ge P; Liao D; Li H; Lyu X; Ai J
    Front Immunol; 2022; 13():898493. PubMed ID: 35812369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
    Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
    Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
    Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
    Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
    [No Abstract]   [Full Text] [Related]  

  • 4. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
    Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
    Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
    Front Immunol; 2021; 12():725223. PubMed ID: 34484235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer.
    Liu R; Yang T; Huang J; Xiao Z; Liu J; Li Z; Tong S
    BMC Cancer; 2024 Aug; 24(1):947. PubMed ID: 39095785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
    Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
    Front Immunol; 2022; 13():965469. PubMed ID: 36090967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACSM6 overexpression indicates a non-inflammatory tumor microenvironment and predicts treatment response in bladder cancer: results from multiple real-world cohorts.
    Li Z; Yao Y; Qi T; Wu Z; Deng D; Liu B
    Front Pharmacol; 2023; 14():1222512. PubMed ID: 37426827
    [No Abstract]   [Full Text] [Related]  

  • 9.
    Zhao X; Hu J; Li J; Gu L; Chen J; Othmane B; Gong G; Yuan J; Deng H
    Dis Markers; 2022; 2022():7147279. PubMed ID: 35909893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
    Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
    Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the immune related lncRNAs in bladder cancer to aid immunotherapy.
    Xiao Y; Dong Y; Yu T; Wang R; Gao Y; Li S; Nong S; Li W
    Front Immunol; 2022; 13():941189. PubMed ID: 36091015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACER2 forms a cold tumor microenvironment and predicts the molecular subtype in bladder cancer: Results from real-world cohorts.
    Liu J; Cheng C; Qi T; Xiao J; Zhou W; Deng D; Dai Y
    Front Genet; 2023; 14():1148437. PubMed ID: 36936425
    [No Abstract]   [Full Text] [Related]  

  • 13. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
    Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
    Front Immunol; 2021; 12():791924. PubMed ID: 34975891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
    Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
    Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer immunity and immunotherapy response in bladder cancer.
    Jia X; Zhang D; Zhou C; Yan Z; Jiang Z; Xie L; Jiang J
    Front Oncol; 2023; 13():1175183. PubMed ID: 37637034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
    Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
    Front Immunol; 2022; 13():964393. PubMed ID: 36211344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GATA3 Predicts the Tumor Microenvironment Phenotypes and Molecular Subtypes for Bladder Carcinoma.
    Zhang Q; Qi T; Long Y; Li X; Yao Y; Wu Q; Zou A; Qthmane B; Liu P
    Front Surg; 2022; 9():860663. PubMed ID: 35647011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia is correlated with the tumor immune microenvironment: Potential application of immunotherapy in bladder cancer.
    Chen H; Zhang Y; Chen X; Xu R; Zhu Y; He D; Cheng Y; Wang Z; Qing X; Cao K
    Cancer Med; 2023 Dec; 12(24):22333-22353. PubMed ID: 38063246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile.
    Peng M
    Front Immunol; 2022; 13():970885. PubMed ID: 36003383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts.
    Deng D; Li X; Qi T; Dai Y; Liu N; Li H
    Front Pharmacol; 2023; 14():1187700. PubMed ID: 37214475
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.